计算溶液所需的质量、体积或浓度。
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
2-8°C储存,干燥。低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase Rifalazil (KRM-1648; ABI-1648) is an antibiotic , exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori , C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB)
In Vitro
Rifalazil exhibits antimicrobal activity against Gram-positive enteric bacteria, inhibits Clostridium difficile , Clostridium perfringens , Bacteroides fragilis with MIC 50 value of 0.0015, 0.0039, 0.0313 µg/ml, respectively. Rifalazil exhibits antimicrobal activity against Gram-negative enteric bacteria, inhibits Escherichia coli and Klebsiella pneumoniae with MIC 50 value of 16 and 16 µg/ml, respectively. Rifalazil exhibits antimicrobal activity against non-enteric Gram-positive bacteria, inhibits Methicillin-susceptible Staphylococcus aureus , Methicillin-resistant S. aureus , Methicillin- and quinolone-resistant S. aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Streptococcus pneumoniae with MIC 50 value of 0.0078, 0.0078, 0.0078, 0.0078, 0.0002, 0.0001 µg/ml, respectively. Rifalazil exhibits antimicrobal activity against Helicobacter pylori , Chlamydia pneumoniae and Chlamydia trachomatis with MIC 50 value of 0.004, 0.000125 and 0.00025 µg/ml, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Rifalazil (oral gavage; 20, 25, and 150 mg/kg; 6-8 weeks) combines with isoniazid (INH) for 6 weeks or greater significantly reduced the number of mice per group in which M. tuberculosis is detected in both spleens and lungs compared to the reductions for the early and late controls. And the addition of Pyrazinamide (PZA) does not significantly improve RLZ-INH therapy at any time point. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female CD-1 mice infected with 5.2 × 10 7 viable mycobacteriaDosage: 20, 25, and 150 mg/kg; 6-8 weeks Administration: Oral gavage Result: Combined with isoniazid (INH) showed its potential for short-course treatment of Mycobacterium tuberculosis infection.
Form:Solid
IC50& Target:IC50: RNA polymerase
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 苯并噁嗪类 |
| 亚类(Subclass) | 吩噁嗪类 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 吩噁嗪类 |
| 其他上位类(Alternative Parents) | N-芳基哌嗪 萘酚及其衍生物 二烷基芳胺 N-烷基哌嗪 缩酮 乙烯基酰胺 乙烯基酸 杂芳族化合物 环状羧酰亚胺酸 三烷基胺 仲醇 羧酸酯 氨基酸及其衍生物 炔丙基型1,3-偶极有机化合物 多元醇 氧环化合物 一元羧酸及其衍生物 二烷基醚 氮杂环化合物 有机光子化合物 有机氧化物 碳氢化合物衍生物 羰基化合物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 1-萘酚 - 1,4-二氮杂环丁烷 - 乙醛酸 - 羟基苯甲酸酯 - 氨基酸 - 氨基酸或其衍生物 - 芳香族杂多环化合物 - 氮杂环 - 苯基化合物 - 羰基 - 羧酸衍生物 - 羧酸酰胺 - 环羧酰胺酸 - 二烷基醚 - 二烷基芳基胺 - 乙醚 - 杂芳香族化合物 - 烃衍生物 - 酮醛 - 单羧酸或其衍生物 - N-烷基哌嗪 - N-芳基哌嗪 - 萘 - 有机1,3-双极性化合物 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氮化合物 - 有机氧化合物 - 有机氮化合物 - 氧杂环 - 苯氧嗪 - 哌嗪 - 多醇 - 丙炔型1,3-双极性有机化合物 - 醛基 - 三元脂肪胺 - 三级脂肪族/芳香族胺 - 三芳基胺 - 乙烯基羧酸 - 乙烯酰胺 |
| 描述(Description) | 该化合物属于苯并噁嗪类有机化合物。这类多环芳香化合物含有苯并噁嗪结构单元,该单元为由两个苯环经1,4-噁嗪环连接而成的线性三环体系。 |
| 外部描述符(External Descriptors) | 暂无 |
| ALogP | 3.3 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|